Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
294 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-04-25
Study Completion Date
2021-10-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Coronary artery disease (CAD) is the most frequent cause of mortality in the industrialized world. Hypercholesterolemia is a major risk factor for the development and progression of CAD. While statins currently represent the first-line, gold-standard therapy for primary and secondary prevention of cardiovascular morbidity and mortality, nearly 50% of patients in Europe and Canada treated with statins do not achieve their target levels of low-density lipoprotein cholesterol (LDL-C) or cannot tolerate effective statin doses.
Recently, a growing number of studies of PCSK9 inhibitors in a wide spectrum of patients with hyperlipidemia on or off lipid-lowering therapy, familial hypercholesterolemia, and statin intolerance demonstrated consistent, profound, and sustained reductions in LDL-C with greater magnitude of reduction as compared with high-dose statin regimens. However, the effects of PCSK9 inhibition on coronary plaque morphology remain unknown.
This study will investigate the effect of the PCSK9 inhibitor alirocumab in patients with acute myocardial infarction undergoing percutaneous coronary intervention (PCI) in the infarct-related artery and receiving guideline-recommended high-intensity statin therapy. A serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study will be performed to determine the change in plaque volume at week 52. A total of 294 patients will be enrolled in the study and randomized in a 1:1 ratio to either alirocumab or placebo.
Recently, a growing number of studies of PCSK9 inhibitors in a wide spectrum of patients with hyperlipidemia on or off lipid-lowering therapy, familial hypercholesterolemia, and statin intolerance demonstrated consistent, profound, and sustained reductions in LDL-C with greater magnitude of reduction as compared with high-dose statin regimens. However, the effects of PCSK9 inhibition on coronary plaque morphology remain unknown.
This study will investigate the effect of the PCSK9 inhibitor alirocumab in patients with acute myocardial infarction undergoing percutaneous coronary intervention (PCI) in the infarct-related artery and receiving guideline-recommended high-intensity statin therapy. A serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study will be performed to determine the change in plaque volume at week 52. A total of 294 patients will be enrolled in the study and randomized in a 1:1 ratio to either alirocumab or placebo.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction
NCT04731155
Early PCSK9 Inhibitor on Ventricular Remodling
RECRUITING
PHASE4
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
NCT05292404
Acute Myocardial Infarction
RECRUITING
PHASE4
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
NCT07276282
Coronary Artery Disease
Acute Myocardial Infarction (AMI)
Coronary Atherosclerosis of Native Coronary Artery
NOT_YET_RECRUITING
PHASE3
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
NCT05604131
Acute Myocardial Infarction Type 1
RECRUITING
PHASE2
Very Early PCSK9 Inhibition for Acute Myocardial Infarction
NCT07208006
Acute Myocardial Infarction (AMI)
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Substudies
* Biobank/drug monitoring, all sites
* Lipidomics (n=294), all sites
* Platelet Function (n=\~150), Bern
* Endothelial Function (n=\~150), Bern
* Neatherosclerosis (n=\~294), all sites
* Neutrophilic Extracellular Trap (NET), (n=\~50), Vienna
* OCT-NIRS/IVUS Matching Substudy (n=\~104), Bern
* Positron Emission Computed Tomography (PET-CT), (n=\~50), Copenhagen
* Shear Stress (n=\~294), London
* Quantitative Flow Ratio (QFR) (n=\~294), Bern
* Biobank/drug monitoring, all sites
* Lipidomics (n=294), all sites
* Platelet Function (n=\~150), Bern
* Endothelial Function (n=\~150), Bern
* Neatherosclerosis (n=\~294), all sites
* Neutrophilic Extracellular Trap (NET), (n=\~50), Vienna
* OCT-NIRS/IVUS Matching Substudy (n=\~104), Bern
* Positron Emission Computed Tomography (PET-CT), (n=\~50), Copenhagen
* Shear Stress (n=\~294), London
* Quantitative Flow Ratio (QFR) (n=\~294), Bern
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Coronary Vessel
Coronary Circulation
Atheroma; Myocardial
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alirocumab
Alirocumab 150 mg/mL, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
Group Type
EXPERIMENTAL
Alirocumab
Intervention Type
DRUG
Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
Placebo
Placebo, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
Group Type
PLACEBO_COMPARATOR
Alirocumab
Intervention Type
DRUG
Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alirocumab
Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female, age ≥18 years at screening;
* Acute myocardial infarction: acute ST-segment elevation myocardial infarction (STEMI) with pain onset within ≤24h, or non-ST segment elevation myocardial infarction (NSTEMI), with at least one coronary segment (culprit lesion) requiring PCI;
* LDL-C ≥70 mg/dL (≥1.8 mmol/L) assessed prior to, or during PCI in patients who have been receiving any stable statin regimen within ≥ 4 weeks prior to enrollment; OR LDL-C ≥125 mg/dL (≥3.2 mmol/L) in patients who are statin-naïve or have not been on stable statin regimen for ≥ 4 weeks prior to enrollment;
* At least two major native coronary arteries ("target vessels") each meeting the following criteria for intracoronary imaging immediately following the qualifying PCI procedure: Angiographic evidence of \<50% reduction in lumen diameter by angiographic visual estimation;
* Target vessel deemed to be accessible to imaging catheters and suitable for intracoronary imaging in the proximal (50mm) segment ("target segment");
* Target vessel may not be a bypass (saphenous vein or arterial) graft or a bypassed native vessel;
* Target vessel must not have undergone previous PCI within the target segment;
* Target vessel is not candidate for intervention at the time of qualifying PCI or over the following 6 months in the judgment of the Investigator;
* Hemodynamic stability allowing the repetitive administration of nitroglycerine;
* Ability to understand the requirements of the study and to provide informed consent;
* Willingness to undergo follow-up intracoronary imaging.
* Acute myocardial infarction: acute ST-segment elevation myocardial infarction (STEMI) with pain onset within ≤24h, or non-ST segment elevation myocardial infarction (NSTEMI), with at least one coronary segment (culprit lesion) requiring PCI;
* LDL-C ≥70 mg/dL (≥1.8 mmol/L) assessed prior to, or during PCI in patients who have been receiving any stable statin regimen within ≥ 4 weeks prior to enrollment; OR LDL-C ≥125 mg/dL (≥3.2 mmol/L) in patients who are statin-naïve or have not been on stable statin regimen for ≥ 4 weeks prior to enrollment;
* At least two major native coronary arteries ("target vessels") each meeting the following criteria for intracoronary imaging immediately following the qualifying PCI procedure: Angiographic evidence of \<50% reduction in lumen diameter by angiographic visual estimation;
* Target vessel deemed to be accessible to imaging catheters and suitable for intracoronary imaging in the proximal (50mm) segment ("target segment");
* Target vessel may not be a bypass (saphenous vein or arterial) graft or a bypassed native vessel;
* Target vessel must not have undergone previous PCI within the target segment;
* Target vessel is not candidate for intervention at the time of qualifying PCI or over the following 6 months in the judgment of the Investigator;
* Hemodynamic stability allowing the repetitive administration of nitroglycerine;
* Ability to understand the requirements of the study and to provide informed consent;
* Willingness to undergo follow-up intracoronary imaging.
Exclusion Criteria
* Left-main disease, defined as ≥50% reduction in lumen diameter of the left main coronary artery by angiographic visual estimation;
* Three-vessel disease, defined as ≥70% reduction in lumen diameter of three major epicardial coronary arteries by angiographic visual estimation or in major branches of one or more of these arteries, irrespective of the localization (proximal 50mm or more distal localization) of the obstructive lesions;
* History of coronary artery bypass surgery;
* "Thrombolysis In Myocardial Infarction" (TIMI) flow \<2 of the infarct-related artery after PCI;
* Unstable clinical status (hemodynamic or electrical instability);
* Significant coronary calcification or tortuosity deemed to preclude IVUS, NIRS and OCT evaluation;
* Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response not controlled by medications in the past 3 months prior to screening;
* Severe renal dysfunction, defined by estimated glomerular filtration rate \<30 ml/min/1.73m2;
* Active liver disease or hepatic dysfunction;
* Known intolerance to rosuvastatin OR known statin intolerance;
* Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel;
* Known sensitivity to any substances to be administered, including known statin intolerance;
* Patients who previously received alirocumab or other PCSK9 inhibitor;
* Patient who received cholesterol ester transfer protein inhibitors in the past 12 months prior to screening;
* Treatment with systemic steroids or systemic cyclosporine in the past 3 months;
* Known active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment of the Investigator;
* Planned surgery within 12 months;
* Patients who will not be available for study-required visits in the judgment of the Investigator;
* Current enrollment in another investigational device or drug study;
* History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer;
* Estimated life expectancy less than 1 year;
* Female of childbearing potential (age \<50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.
* Three-vessel disease, defined as ≥70% reduction in lumen diameter of three major epicardial coronary arteries by angiographic visual estimation or in major branches of one or more of these arteries, irrespective of the localization (proximal 50mm or more distal localization) of the obstructive lesions;
* History of coronary artery bypass surgery;
* "Thrombolysis In Myocardial Infarction" (TIMI) flow \<2 of the infarct-related artery after PCI;
* Unstable clinical status (hemodynamic or electrical instability);
* Significant coronary calcification or tortuosity deemed to preclude IVUS, NIRS and OCT evaluation;
* Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response not controlled by medications in the past 3 months prior to screening;
* Severe renal dysfunction, defined by estimated glomerular filtration rate \<30 ml/min/1.73m2;
* Active liver disease or hepatic dysfunction;
* Known intolerance to rosuvastatin OR known statin intolerance;
* Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel;
* Known sensitivity to any substances to be administered, including known statin intolerance;
* Patients who previously received alirocumab or other PCSK9 inhibitor;
* Patient who received cholesterol ester transfer protein inhibitors in the past 12 months prior to screening;
* Treatment with systemic steroids or systemic cyclosporine in the past 3 months;
* Known active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment of the Investigator;
* Planned surgery within 12 months;
* Patients who will not be available for study-required visits in the judgment of the Investigator;
* Current enrollment in another investigational device or drug study;
* History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer;
* Estimated life expectancy less than 1 year;
* Female of childbearing potential (age \<50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regeneron Pharmaceuticals
INDUSTRY
Sponsor Role
collaborator
Insel Gruppe AG, University Hospital Bern
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lorenz Raeber, Prof., MD
Role: PRINCIPAL_INVESTIGATOR
Bern Universitiy Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Vienna (AKH)
Vienna, , Austria
Site Status
Rigshospitalet
Copenhagen, , Denmark
Site Status
Radboud Univerity, Nijmegen Medical Centre
Nijmegen, Gelderland, Netherlands
Site Status
Erasmus Thoraxcentre
Rotterdam, , Netherlands
Site Status
Basel University Hospital
Basel, , Switzerland
Site Status
Bern University Hospital Inselspital
Bern, , Switzerland
Site Status
Hopitaux Universitaires Geneve
Geneva, , Switzerland
Site Status
Stadtspital Triemli
Zurich, , Switzerland
Site Status
University Hospital Zurich USZ
Zurich, , Switzerland
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Austria
Denmark
Netherlands
Switzerland
References
Explore related publications, articles, or registry entries linked to this study.
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE. Effect of Evolocumab on Coronary Plaque Composition. J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021. doi: 10.1016/j.jacc.2018.06.078.
Reference Type
BACKGROUND
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951.
Reference Type
BACKGROUND
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002. Epub 2013 Nov 12. No abstract available.
Reference Type
RESULT
Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM; ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015 May 14;36(19):1186-94. doi: 10.1093/eurheartj/ehv028. Epub 2015 Feb 16.
Reference Type
RESULT
Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J, Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015 Nov 14;36(43):2996-3003. doi: 10.1093/eurheartj/ehv370. Epub 2015 Sep 1.
Reference Type
RESULT
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.
Reference Type
RESULT
Koskinas KC, Ughi GJ, Windecker S, Tearney GJ, Raber L. Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment. Eur Heart J. 2016 Feb 7;37(6):524-35a-c. doi: 10.1093/eurheartj/ehv642. Epub 2015 Dec 11.
Reference Type
RESULT
Raber L, Taniwaki M, Zaugg S, Kelbaek H, Roffi M, Holmvang L, Noble S, Pedrazzini G, Moschovitis A, Luscher TF, Matter CM, Serruys PW, Juni P, Garcia-Garcia HM, Windecker S; IBIS 4 (Integrated Biomarkers and Imaging Study-4) Trial Investigators (NCT00962416). Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Eur Heart J. 2015 Feb 21;36(8):490-500. doi: 10.1093/eurheartj/ehu373. Epub 2014 Sep 2.
Reference Type
RESULT
Pu J, Mintz GS, Brilakis ES, Banerjee S, Abdel-Karim AR, Maini B, Biro S, Lee JB, Stone GW, Weisz G, Maehara A. In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy. Eur Heart J. 2012 Feb;33(3):372-83. doi: 10.1093/eurheartj/ehr387. Epub 2011 Oct 20.
Reference Type
RESULT
Maehara A, Cristea E, Mintz GS, Lansky AJ, Dressler O, Biro S, Templin B, Virmani R, de Bruyne B, Serruys PW, Stone GW. Definitions and methodology for the grayscale and radiofrequency intravascular ultrasound and coronary angiographic analyses. JACC Cardiovasc Imaging. 2012 Mar;5(3 Suppl):S1-9. doi: 10.1016/j.jcmg.2011.11.019.
Reference Type
RESULT
Madder RD, Goldstein JA, Madden SP, Puri R, Wolski K, Hendricks M, Sum ST, Kini A, Sharma S, Rizik D, Brilakis ES, Shunk KA, Petersen J, Weisz G, Virmani R, Nicholls SJ, Maehara A, Mintz GS, Stone GW, Muller JE. Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2013 Aug;6(8):838-46. doi: 10.1016/j.jcin.2013.04.012. Epub 2013 Jul 17.
Reference Type
RESULT
Raber L, Zanchin T, Baumgartner S, Taniwaki M, Kalesan B, Moschovitis A, Garcia-Garcia HM, Justiz J, Pilgrim T, Wenaweser P, Meier B, Juni P, Windecker S. Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: an optical coherence tomography study. Int J Cardiol. 2014 May 1;173(2):259-67. doi: 10.1016/j.ijcard.2014.02.036. Epub 2014 Feb 28.
Reference Type
RESULT
Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, Bouma B, Bruining N, Cho JM, Chowdhary S, Costa MA, de Silva R, Dijkstra J, Di Mario C, Dudek D, Falk E, Feldman MD, Fitzgerald P, Garcia-Garcia HM, Gonzalo N, Granada JF, Guagliumi G, Holm NR, Honda Y, Ikeno F, Kawasaki M, Kochman J, Koltowski L, Kubo T, Kume T, Kyono H, Lam CC, Lamouche G, Lee DP, Leon MB, Maehara A, Manfrini O, Mintz GS, Mizuno K, Morel MA, Nadkarni S, Okura H, Otake H, Pietrasik A, Prati F, Raber L, Radu MD, Rieber J, Riga M, Rollins A, Rosenberg M, Sirbu V, Serruys PW, Shimada K, Shinke T, Shite J, Siegel E, Sonoda S, Suter M, Takarada S, Tanaka A, Terashima M, Thim T, Uemura S, Ughi GJ, van Beusekom HM, van der Steen AF, van Es GA, van Soest G, Virmani R, Waxman S, Weissman NJ, Weisz G; International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT). Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012 Mar 20;59(12):1058-72. doi: 10.1016/j.jacc.2011.09.079.
Reference Type
RESULT
van der Velpen V, Haner JD, Kakizaki R, Bar S, Ueki Y, Siontis GCM, Stortecky S, Biccire FG, Ambuhl M, Kaiser C, Iglesias JF, Mach F, van Geuns RJ, Daemen J, Engstrom T, Ondracek AS, Lang I, Bourantas CV, Matter CM, Windecker S, Koskinas KC, Mayr M, Losdat S, Raber L, Haschke M, Spirk D. Intake of high-intensity statin after acute myocardial infarction assessed by direct drug concentration measurement: association with LDL-C response and coronary plaque modifications in the PACMAN-AMI trial. Eur J Prev Cardiol. 2025 Aug 12:zwaf457. doi: 10.1093/eurjpc/zwaf457. Online ahead of print.
Reference Type
DERIVED
Koskinas KC, Haner J, Ueki Y, Otsuka T, Lonborg J, Shibutani H, Kakizaki R, Kaiser C, van Geuns RJ, Ondracek AS, Praz F, Ambuhl M, Spirk D, Lanz J, Daemen J, Heg D, Mayr M, Mach F, Windecker S, Engstrom T, Lang IM, von Eckardstein A, Losdat S, Raber L. Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab. Circ Cardiovasc Imaging. 2024 Nov;17(11):e016683. doi: 10.1161/CIRCIMAGING.124.016683. Epub 2024 Nov 19.
Reference Type
DERIVED
Biccire FG, Kakizaki R, Koskinas KC, Ueki Y, Haner J, Shibutani H, Lonborg J, Spitzer E, Iglesias JF, Otsuka T, Siontis GCM, Stortecky S, Kaiser C, Ambuhl M, Morf L, Ondracek AS, van Geuns RJ, Spirk D, Daemen J, Mach F, Windecker S, Engstrom T, Lang I, Losdat S, Raber L. Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial. JAMA Cardiol. 2024 Dec 1;9(12):1082-1092. doi: 10.1001/jamacardio.2024.3200.
Reference Type
DERIVED
Rexhaj E, Bar S, Soria R, Ueki Y, Haner JD, Otsuka T, Kavaliauskaite R, Siontis GC, Stortecky S, Shibutani H, Spirk D, Engstrom T, Lang I, Morf L, Ambuhl M, Windecker S, Losdat S, Koskinas KC, Raber L; PACMAN-AMI Investigators. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy. Atherosclerosis. 2024 May;392:117504. doi: 10.1016/j.atherosclerosis.2024.117504. Epub 2024 Mar 6.
Reference Type
DERIVED
Biccire FG, Haner J, Losdat S, Ueki Y, Shibutani H, Otsuka T, Kakizaki R, Hofbauer TM, van Geuns RJ, Stortecky S, Siontis GCM, Bar S, Lonborg J, Heg D, Kaiser C, Spirk D, Daemen J, Iglesias JF, Windecker S, Engstrom T, Lang I, Koskinas KC, Raber L. Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy. J Am Coll Cardiol. 2023 Oct 31;82(18):1737-1747. doi: 10.1016/j.jacc.2023.08.019. Epub 2023 Aug 26.
Reference Type
DERIVED
Bar S, Kavaliauskaite R, Otsuka T, Ueki Y, Haner JD, Siontis GCM, Stortecky S, Shibutani H, Temperli F, Kaiser C, Iglesias JF, Jan van Geuns R, Daemen J, Spirk D, Engstrom T, Lang I, Windecker S, Koskinas KC, Losdat S, Raber L. Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial. EuroIntervention. 2023 Jul 17;19(4):e286-e296. doi: 10.4244/EIJ-D-23-00201.
Reference Type
DERIVED
Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, Radu Juul Jensen MD, Zanchin C, Stortecky S, Spirk D, Siontis GCM, Saleh L, Matter CM, Daemen J, Mach F, Heg D, Windecker S, Engstrom T, Lang IM, Koskinas KC; PACMAN-AMI collaborators. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022 May 10;327(18):1771-1781. doi: 10.1001/jama.2022.5218.
Reference Type
DERIVED
Zanchin C, Koskinas KC, Ueki Y, Losdat S, Haner JD, Bar S, Otsuka T, Inderkum A, Jensen MRJ, Lonborg J, Fahrni G, Ondracek AS, Daemen J, van Geuns RJ, Iglesias JF, Matter CM, Spirk D, Juni P, Mach F, Heg D, Engstrom T, Lang I, Windecker S, Raber L. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial. Am Heart J. 2021 Aug;238:33-44. doi: 10.1016/j.ahj.2021.04.006. Epub 2021 May 2.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-01382
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895
RECRUITING
PHASE3
Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes
NCT03113773
COMPLETED
PHASE1/PHASE2
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
NCT01020383
COMPLETED
PHASE2
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT04153149
ACTIVE_NOT_RECRUITING
PHASE3
The Use of Statins for Myocardial Death Prevention
NCT00772564
COMPLETED
PHASE4
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
NCT00809965
COMPLETED
PHASE3
Direct Complete Versus Staged Complete Revascularization in Patients Presenting With Acute Coronary Syndromes and Multivessel Disease
NCT03621501
ACTIVE_NOT_RECRUITING
NA
Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients
NCT01502774
COMPLETED
PHASE3
In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction
NCT05184530
COMPLETED
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
NCT03473223
COMPLETED
PHASE3
A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
NCT01327183
COMPLETED
PHASE2
Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility
NCT05160311
UNKNOWN
NA
Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock
NCT01901471
WITHDRAWN
PHASE2
Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)
NCT00133003
COMPLETED
PHASE4
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
NCT01442038
COMPLETED
PHASE3
Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry"
NCT05164640
COMPLETED
NA
Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention
NCT04571580
TERMINATED
PHASE3
Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty
NCT00354406
COMPLETED
PHASE4
Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction
NCT03991143
COMPLETED
PHASE2
Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty
NCT02205775
TERMINATED
PHASE3
A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
NCT04284995
COMPLETED
PHASE2
A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI
NCT06155110
COMPLETED
PHASE4
A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
NCT05427786
RECRUITING
PHASE4
Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients
NCT00379418
COMPLETED